ESRRA and obesity disorder: Consistent with the results obtained using ERRα-null mice as a model, treatment with the inverse agonist C29 led to normalized insulin and circulating triglyceride levels, improved insulin sensitivity and glucose tolerance in diet-induced obesity (DIO) mouse models as well as an overt diabetic rat model (100).